Research progress of cytokines and ophthalmic diseases

doi:10.3877/cma.j.issn.2095-2007.2022.02.010

Abstract

Abstract:

Cytokines, known as "communication language between cells", are involved in the physiological and pathological processes of tissues and body organs. Investigating cytokines and eye diseases can not only reveal the molecular mechanism of their pathogenesis, but also monitor the indicators of cytokines, which can also be used to make the diagnosis, predict the outcome of the disease, clarify the timing of disease intervention, and help to formulate new targeted treatment strategies. The concept and research origin of cytokines about eye diseases such as diabetes ophthalmopathy, retinal vein occlusion, age-related macular degeneration, autoimmune uveitis, glaucomatous optic neuropathy, proliferative vitreoretino-pathy and retinopathy of prematurity were reviewed in this study.

Key words: Cytokines, Eye diseases, Molecular mechanism

Jian Li, Yong Tao, Shuyi Li, Xiaohua Zhang, Yongping Hu. Research progress of cytokines and ophthalmic diseases[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2022, 12(02): 115-119.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2022.02.010

https://zhykyxzz.cma-cmc.com.cn/EN/Y2022/V12/I02/115

References 56

[1]	Oppenheim JJ. Cytokines: past, present, and future[J]. Int J Hematol, 2001, 74(1): 3-8.
[2]	Dumonde DC, Wolstencroft RA, Panayi GS, et al. Lymphokines: non-antibody mediators of cellular immunity generated by lymphocyte activation[J]. Nature, 1969, 224(5214): 38-42.
[3]	Cohen S, Bigazzi PE, Yoshida T. Commentary. Similarities of T cell function in cell-mediated immunity and antibody production[J]. Cell Immunol, 1974, 12(1): 150-159.
[4]	Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression[J]. Lancet, 2020, 395(10229): 1033-1034.
[5]	Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss[J]. Eye and vision, 2015, 2: 17.
[6]	Wang W, Lo ACY. Diabetic Retinopathy: Pathophysiology and Treatments[J]. International journal of molecular sciences, 2018, 19(6): 1816.
[7]	Apte RS, Chen DS, Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development[J]. Cell, 2019, 176(6): 1248-1264.
[8]	Murakami T, Frey T, Lin C, et al. Protein kinase cbeta phosphorylates occludin regulating tight junction trafficking in vascular endothelial growth factor-induced permeability in vivo[J]. Diabetes, 2012, 61(6): 1573-1583.
[9]	Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen[J]. Science, 1989, 246(4935): 1306-1309.
[10]	Simo-Servat O, Hernandez C, Simo R. Usefulness of the vitreous fluid analysis in the translational research of diabetic retinopathy[J]. Mediators of inflammation, 2012: 872978.
[11]	Dong N, Xu B, Wang B, et al. Study of 27 aqueous humor cytokines in patients with type 2 diabetes with or without retinopathy[J]. Mol Vis, 2013, 19: 1734-1746.
[12]	Kimura A, Kishimoto T. IL-6: regulator of Treg/Th17 balance[J]. Eur J Immunol, 2010, 40(7): 1830-1835.
[13]	Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease[J]. Cold Spring Harb Perspect Biol, 2014, 6(10): a016295.
[14]	Kowluru RA, Odenbach S. Role of interleukin-1beta in the pathogenesis of diabetic retinopathy[J]. Br J Ophthalmol, 2004, 88(10): 1343-1347.
[15]	Carmi Y, Dotan S, Rider P, et al. The role of IL-1beta in the early tumor cell-induced angiogenic response[J]. J Immunol, 2013, 190(7): 3500-3509.
[16]	Lee WJ, Kang MH, Seong M, et al. Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusion[J]. Br J Ophthalmol, 2012, 96(11): 1426-1430.
[17]	Hernandez C, Segura RM, Fonollosa A, et al. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy[J]. Diabet Med, 2005, 22(6): 719-722.
[18]	Aveleira CA, Lin CM, Abcouwer SF, et al. TNF-alpha signals through PKCzeta/NF-kappaB to alter the tight junction complex and increase retinal endothelial cell permeability[J]. Diabetes, 2010, 59(11): 2872-2882.
[19]	Taghavi Y, Hassanshahi G, Kounis NG, et al. Monocyte chemoattractant protein-1 (MCP-1/CCL2) in diabetic retinopathy: latest evidence and clinical considerations[J]. J Cell Commun Signal, 2019, 13(4): 451-462.
[20]	Joussen AM, Poulaki V, Le ML, et al. A central role for inflammation in the pathogenesis of diabetic retinopathy[J]. FASEB journal, 2004, 18(12): 1450-1452.
[21]	Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy[J]. Semin Immunopathol, 2008, 30(2): 65-84.
[22]	Antonetti DA, Barber AJ, Hollinger LA, et al. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1[J]. J Biol Chem, 1999, 274(33): 23463-23467.
[23]	Noma H, Funatsu H, Mimura T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor in macular edema with central retinal vein occlusion[J]. Ophthalmology, 2009, 116(1): 87-93.
[24]	Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders[J]. N Engl J Med, 1994, 331(22): 1480-1487.
[25]	Noma H, Yasuda K, Mimura T, et al. Relationship between retinal blood flow and cytokines in central retinal vein occlusion[J]. BMC Ophthalmol, 2020, 20(1): 215.
[26]	Noma H, Mimura T, Yasuda K, et al. Role of soluble vascular endothelial growth factor receptor signaling and other factors or cytokines in central retinal vein occlusion with macular edema[J]. Invest Ophthalmol Vis Sci, 2015, 56(2): 1122-1128.
[27]	Yu H, Huang X, Ma Y, et al. Interleukin-8 regulates endothelial permeability by down-regulation of tight junction but not dependent on integrins induced focal adhesions[J]. Int J Biol Sci, 2013, 9(9): 966-979.
[28]	Lee YR, Liu MT, Lei HY, et al. MCP-1, a highly expressed chemokine in dengue haemorrhagic fever/dengue shock syndrome patients, may cause permeability change, possibly through reduced tight junctions of vascular endothelium cells[J]. J Gen Virol, 2006, 87(12): 3623-3630.
[29]	Koss M, Pfister M, Rothweiler F, et al. Correlation from undiluted vitreous cytokines of untreated central retinal vein occlusion with spectral domain optical coherence tomography[J]. Open Ophthalmol J, 2013, 7: 11-17.
[30]	Elner SG, Elner VM, Pavilack MA, et al. Modulation and function of intercellular adhesion molecule-1 on human retinal pigment epithelial cells[J]. Lab Invest, 1992, 66(2): 200-211.
[31]	Miyamoto K, Khosrof S, Bursell SE, et al. Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition[J]. Proc Natl Acad Sci USA, 1999, 96(19): 10836-10841.
[32]	Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040[J]. Lancet Glob Health, 2014, 2(2): 106-116.
[33]	Wang K, Li H, Sun R, et al. Emerging roles of transforming growth factor beta signaling in wet age-related macular degeneration[J]. Acta Biochim Biophys Sin (Shanghai), 2019, 51(1): 1-8.
[34]	Joo JH, Kim H, Shin JH, et al. Aqueous humor cytokine levels through microarray analysis and a sub-analysis based on optical coherence tomography in wet age-related macular degeneration patients[J]. BMC Ophthalmol, 2021, 21(1): 399.
[35]	Celkova L, Doyle SL, Campbell M. NLRP3 Inflammasome and Pathobiology in AMD[J]. J Clin Med, 2015, 4(1): 172-192.
[36]	Al-Gayyar MM, Elsherbiny NM. Contribution of TNF-alpha to the development of retinal neurodegenerative disorders[J]. Eur Cytokine Netw, 2013, 24(1): 27-36.
[37]	Nagineni CN, Kommineni VK, Ganjbaksh N, et al. Inflammatory Cytokines Induce Expression of Chemokines by Human Retinal Cells: Role in Chemokine Receptor Mediated Age-related Macular Degeneration[J]. Aging Dis, 2015, 6(6): 444-455.
[38]	Paraoan L, Sharif U, Carlsson E, et al. Secretory proteostasis of the retinal pigmented epithelium: Impairment links to age-related macular degeneration[J]. Prog Retin Eye Res, 2020, 79: 100859.
[39]	von Essen MR, Sondergaard HB, Petersen ERS, et al. IL-6, IL-12, and IL-23 STAT-Pathway Genetic Risk and Responsiveness of Lymphocytes in Patients with Multiple Sclerosis[J]. Cells, 2019, 8(3): 285.
[40]	Karkhur S, Hasanreisoglu M, Vigil E, et al. Interleukin-6 inhibition in the management of non-infectious uveitis and beyond[J]. J Ophthalmic Inflamm Infect, 2019, 9(1): 17.
[41]	Guo K, Zhang X. Cytokines that Modulate the Differentiation of Th17 Cells in Autoimmune Uveitis[J]. J Immunol Res, 2021: 6693542.
[42]	Zhong Z, Su G, Kijlstra A, et al. Activation of the interleukin-23/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis[J]. Prog Retin Eye Res, 2021, 80: 100866.
[43]	Gupta S, Shyamsundar K, Agrawal M, et al. Current Knowledge of Biologics in Treatment of Noninfectious Uveitis[J]. J Ocul Pharmacol Ther, 2022, 38(3): 203-222.
[44]	Atienza-Mateo B, Calvo-Rio V, Beltran E, et al. Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Behcet's disease: multicentre retrospective study[J]. Rheumatology (Oxford), 2018, 57(5): 856-864.
[45]	Fabiani C, Vitale A, Rigante D, et al. The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behcet's Disease[J]. Ocul Immunol Inflamm, 2020, 28(2): 298-304.
[46]	Vernazza S, Oddone F, Tirendi S, et al. Risk Factors for Retinal Ganglion Cell Distress in Glaucoma and Neuroprotective Potential Intervention[J]. International journal of molecular sciences, 2021, 22(15): 7994.
[47]	Wang Y, Chen S, Liu Y, et al. Inflammatory cytokine profiles in eyes with primary angle-closure glaucoma[J]. Biosci Rep, 2018, 38(6): BSR20181411.
[48]	Zhang JL, Song XY, Chen YY, et al. Novel inflammatory cytokines (IL-36, 37, 38) in the aqueous humor from patients with chronic primary angle closure glaucoma[J]. Int Immunopharmacol, 2019, 71: 164-168.
[49]	Rasoulinejad SA, Karkhah A, Paniri A, et al. Contribution of inflammasome complex in inflammatory-related eye disorders and its implications for anti-inflammasome therapy[J]. Immunopharmacol Immunotoxicol, 2020, 42(5): 400-407.
[50]	Mudhar HS. A brief review of the histopathology of proliferative vitreoretinopathy[J]. Eye (Lond), 2020, 34(2): 246-250.
[51]	Wang ZY, Zhang Y, Chen J, et al. Artesunate inhibits the development of PVR by suppressing the TGF-beta/Smad signaling pathway[J]. Exp Eye Res, 2021, 213: 108859.
[52]	Lei H, Velez G, Hovland P, et al. Growth factors outside the PDGF family drive experimental PVR[J]. Invest Ophthalmol Vis Sci, 2009, 50(7): 3394-3403.
[53]	Chen X, Yang W, Deng X, et al. Interleukin-6 promotes proliferative vitreoretinopathy by inducing epithelial-mesenchymal transition via the JAK1/STAT3 signaling pathway[J]. Mol Vis, 2020, 26: 517-529.
[54]	Hartnett ME, Penn JS. Mechanisms and management of retinopathy of prematurity[J]. N Engl J Med, 2012, 367(26): 2515-2526.
[55]	Hartnett ME. Role of cytokines and treatment algorithms in retinopathy of prematurity[J]. Curr Opin Ophthalmol, 2017, 28(3): 282-288.
[56]	Aher SM, Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants[J]. Cochrane Database Syst Rev, 2020, 2(2): CD004865.

Please choose a citation manager

Content to export